Group 1: Company Overview - Zhejiang Haixiang Pharmaceutical Co., Ltd. is a global supplier of the penem industry chain, providing high-level intermediates and active pharmaceutical ingredients (APIs) [1] - The company is actively expanding strategic customer collaborations and optimizing customer structure [1] Group 2: Market and Financial Insights - The revenue scale and profitability of the penem series are expected to improve continuously, although there is uncertainty due to market price fluctuations [1] - In 2022, raw material price fluctuations had a significant impact, but the company has implemented various strategies to mitigate these effects, including long-term price locking with suppliers [1] Group 3: CMO/CDMO Developments - The company has seen unexpected growth in new project collaborations, particularly with European clients for Phase III clinical projects [2] - Future capital investments are expected to decrease compared to previous years, focusing on expanding CMO/CDMO capacity and enhancing the sterile system construction [2]

Group 1: Company Overview and Market Position - Zhejiang Haixiang Pharmaceutical Co., Ltd. is a global supplier of the full industrial chain for the Penam series, having established an independent Penam production facility in compliance with European and American drug regulations [1] - In the first three quarters of 2022, revenue from the Penam series increased by over 7% year-on-year, indicating significant growth potential as hospital admissions gradually recover [1] Group 2: Production Capacity and New Product Development - The company has completed the expansion of the entire Penam industrial chain within six months, with production capacity continuously increasing [1] - The production lines for active pharmaceutical ingredients (API) and sterile powder injections have been installed and are currently in the validation production phase [1] - The company is actively developing new products, including oral formulations and pediatric Penam, with over ten new products in the pipeline, some reaching pilot and validation production stages [2] Group 3: Research and Development Initiatives - The company is leveraging new technologies and processes to innovate existing products, reduce costs, and enhance competitiveness [2] - A new multi-functional CDMO workshop is planned to improve research and development efficiency, with the Shanghai research institute focusing on front-end process development and the Taizhou research institute on production scaling [2] Group 4: Strategic Growth and Investment - The company is committed to organic growth in the pharmaceutical sector while also considering external acquisition opportunities to strengthen its competitive advantage [2] - Suzhou Sihua, a 32.67% owned subsidiary, is performing well and represents a long-term investment for the company [2]

Group 1: Company Overview - The company is Zhejiang Haixiang Pharmaceutical Co., Ltd., with stock code 002099 [1] - The meeting took place on September 14, 2015, at Taizhou Liting Phoenix Mountain Villa [1] Group 2: Dye Products - Recent price trends for dye products show that the price of Reactive Blue has been stable with slight fluctuations [2] - The KN-R project has a designed capacity of 8,000 tons, which is currently fully operational, while the second phase is under construction and expected to be completed next year [2] - The company is a market leader in KN-R, holding a significant market share and being a drafter of national and industry standards [2] Group 3: Future Development Plans - The company plans to expand its product range by introducing over ten new products, including reactive and acid dyes, to reduce reliance on a single product for revenue [2] - New projects are backed by feasibility studies, ensuring that sales can absorb the increased production capacity [3] Group 4: Pharmaceutical Sector - The pharmaceutical segment has seen resource integration and refined management, resulting in a year-on-year gross margin increase of 2.7% [3] - Breakthroughs in formulation and custom processing businesses have significantly improved profitability, with Haikuo Biological expected to achieve a reduction in losses by the end of the year [3]

证券代码：002099 证券简称：海翔药业 浙江海翔药业股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | --- | |--------------|------------------------------|-------|--------------------------|--------------------| | | | | | 编号： 2015-001 | | | ■ | | 特定对象调研 □分析师会议 | | | | □ | | 媒体采访 □业绩说明会 | | | 投资者关系 | □ 新闻发布会 □路演活动 | | | | | 活动类别 | □ 现场参观 | | | | | | □ 其他 | | | | | 参与单位名称 | 光大证券胡银玉、榕树投资黄俊 | | | | | 及人员姓名 | | | | | | 时间 | 2015 年 5 月 6 日 | | | | | 地点 | 浙江省台州市椒江区解放南路 | 77-1 | | 号台州丽廷凤凰山庄 | | | 议事厅 | | | | | | 董事长：李维金 | | | | | 上市公司接待 | 财务总监：叶 ...

证券代码：002099 证券简称：海翔药业 浙江海翔药业股份有限公司投资者关系活动记录表 编号：2014-006 | --- | --- | --- | --- | |------------|--------------------------|----------------------------------------------------------|-----------------------------------------| | | | | | | | □ | 特定对象调研 □分析师会议 | | | | □ | 媒体采访 □业绩说明会 | | | 投资者关系 | □ | 新闻发布会 ■路演活动 | | | 活动类别 | □ 现场参观 | | | | | □ 其他 | | | | | 信业股权投资管理有限公司 | - | 任晓宁、扬州日兴生物科技股份有 | | | | 限公司-张超、湖南兴湘创富投资有限公司-刘凌、深圳市普邦恒 | | | | 升投资有限公司 - | | 郭德琦、太平洋资产管理有限责任公司-王天 | | | | 卫、东方证券-王漪昆、长江证券股-黄伟轩、太平资产管理有限 | ...

编号：2015-003 ■特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系 □新闻发布会 □路演活动 活动类别 □现场参观 □其他 华富基金翁海波，广发证券冯鹏，华夏基金张钧，招商基 参与单位名称 金梅梅，博时基金葛晨，国泰君安资管李子波，万家基金 及人员姓名 王霄音，广发资管毛丁丁，宝盈基金郝淼，上海道仁资管 姚宏福，交易施罗德张胤 证券代码：002099 证券简称：海翔药业 浙江海翔药业股份有限公司投资者关系活动记录表 | --- | --- | |--------------|-------------------------------------------------| | 时间 | 2015 年 11 月 5 日 | | 地点 | 浙江省台州市椒江区外沙支路 100 号公司会议室 | | 上市公司接待 | 董事会秘书：许华青 | | 人员姓名 | 证券事务代表：蒋如东 | | --- | --- | |------------|-------------------------------------------------------------| | | | | 投资者关系 ...

证券代码：002099 证券简称：海翔药业 浙江海翔药业股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | |-----------------------|------------------------|--------------------------------------------------|----------------------------| | | | | 编号： 2016-003 | | | ■ | 特定对象调研 □分析师会议 | | | | □ | 媒体采访 □业绩说明会 | | | 投资者关系 | □ 新闻发布会 □路演活动 | | | | 活动类别 | □ 现场参观 | | | | | □ 其他 | | | | 参与单位名称 | | 中银国际徐翔、长安信托茅玉峰、民生银行付辉、刘小 | | | 及人员姓名 | 伟、安信证券孙琦祥 | | | | 时间 | 2016 年 7 月 1 | 日 | | | 地点 | | 浙江省台州市椒江区外沙支路 100 | 号公司会议室 | | | 董事会秘书：许华青 | | | | 上市公司接待 人员姓名 | ...